Author:
Ghose Aruni,Lapitan Patricia,Apte Vedika,Ghosh Adheesh,Kandala Abhinav,Basu Sreejana,Parkes Jo,Shinde Sayali D.,Boussios Stergios,Sharma Anand,Das Prantik,Vasdev Nikhil,Rebuzzi Sara E.,Ürün Yüksel,Kanesvaran Ravindran,Maniam Akash,Banna Giuseppe L.
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3(4):386–90.
2. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–8.
3. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975;35(5):1175–81.
4. Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, et al. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Med Chem. 1989;32(3):548–55.
5. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261(5118):212–5.